1.Clinical research progress of Danhong injection in patients with ischemic cerebrovascular diseases
China Modern Doctor 2014;(35):152-153
Danhong injection is mainly salvia miltiorrhiza , safflower extract of Chinese medicine injection preparation , such as pulse ShuLao with promoting blood circulation to remove blood stasis , etc. Function. Of salvia miltiorrhiza in the cold-induced febride records , for the labiatae plants of salvia miltiorrhiza on the root and rhizome , its medicinal bitter, cold, for centering, pericardium, liver meridian. With activating blood regulate the menstrual function , dis-pelling stasis pain , cold blood carbuncle , except vexed sedative effect. Red flower in compendium of material medica in the new record , of compositae safflower dry flowers. Its medicinal sheen , warm. For centering , liver. With activat-ing blood regulate the menstrual function , dispelling stasis the main efficacy of pain relief. Salvia miltiorrhiza injection is widely used in clinical , this article mainly is the progress in the application of salvia miltiorrhiza injection in cere-brovascular disease.
2.Levosimendan combined with Shengmai injection for the treatment of pump failure in 55 patients with acute myocardial infarction
Guixia LUAN ; Xueli ZHAO ; Xin ZHENG
Chinese Journal of Primary Medicine and Pharmacy 2022;29(1):23-27
Objective:To investigate the effects of levosimendan combined with Shengmai injection on pump failure in patients with acute myocardial infarction and its effects on tissue perfusion and oxygen metabolism. Methods:A total of 110 patients with acute myocardial infarction and pump failure who received treatment in Jiaozhou People's Hospital (South Branch) from July 2019 to December 2020 were included in this study. They were randomly assigned to receive either routine treatments including electrocardiography monitoring, oxygen saturation monitoring, oxygen therapy, dual antiplatelet therapy, statins, vasoactive drugs, and nitrates (control group, n = 55) or levosimendan combined with Shengmai injection based on routine treatments (observation group, n = 55) for 10 successive days. Curative efficacy, cardiac function, tissue perfusion, and oxygen metabolism capacity were compared between the control and observation groups. The 1-month mortality rate was compared between the two groups. Results:Total effective rate was significantly higher in the observation group than in the control group [58.18% (32/55) vs. 38.18% (21/55), χ2 = 4.41, P < 0.05]. After treatment, left ventricular end-diastolic diameter, left ventricular ejection fraction, and stroke volume were superior in the observation group to in the control group ( t = 2.12, –5.85, –7.33, all P < 0.05). Oxygen partial pressure, oxygenation index, central venous oxygen saturation, lactate, lactate clearance rate, and urine volume in the observation group were (103.53 ± 9.85) mmHg, (247.69 ± 18.95) mmHg, (77.56 ± 3.59)%, (3.02 ± 0.45) mmol/L, (42.89 ± 5.22)%, (40.88 ± 1.64) mL/hour, respectively, and they were (95.47 ± 11.98) mmHg, (194.69 ± 16.52) mmHg, (70.88 ± 2.13)%, (3.58 ± 0.51) mmol/L, (36.89 ± 5.14)%, and (36.55 ± 2.23) mL/hour, respectively in the observation group. There were significant differences in these indices between the control and observation groups ( t = –3.85, –15.64, –11.87, 3.11, –6.07, –11.27, all P < 0.001). At 1 month of follow-up, mortality rate was significantly lower in the observation group than in the control group [3.64% (2/55) vs. 16.36% (9/55), χ2 = 4.95, P < 0.05]. Conclusion:Levosimendan combined with Shengmai injection is a highly effective treatment for pump failure in acute myocardial infarction. It can improve cardiac function and tissue perfusion, increase oxygen metabolism capacity, and decrease mortality.